Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00545974 · ClinicalTrials.gov registry record · Phase 4
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT00545974 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 81 participants.
The verdict
NCT00545974, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. The secondary objective of the study is to assess the safety and tolerability of long-term treatment with memantine in patients with frontotemporal dementia (FTD) or semantic dementia (SD). To determine whether memantine is effective in slowing the rate of cognitive decline in frontotemporal dementia. To evaluate whether memantine delays or decreases the emergence of parkinsonism in frontotemporal dementia. The tertiary objective of the study is to determine whether treatment with memantine affects changes in weight
Interventions
- DRUG Placebo pill
- DRUG memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00545974
The ClinicalTrials.gov registry entry for NCT00545974 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo pill is the first listed.
NCT00545974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00545974 about?
NCT00545974 is a clinical study titled "Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia". The primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. The secondary objective of the study is to assess the safety and tolerability of long-term treatment with memantine in patients with frontotemporal...
What is the current status of trial NCT00545974?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2007-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00545974?
The interventions under investigation include: Placebo pill (DRUG), memantine (DRUG).
Who is sponsoring clinical trial NCT00545974?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.